Results 181 to 190 of about 17,769,272 (338)

Efficacy and Cost-Effectiveness of Low-Dose vs Standard Dose Prophylaxis for Hemophilia in Indonesia: A Systematic Review [PDF]

Pradana Zaky Romadhon,1,2 Kamila Auliya,2 Made Oka Heryana,2 Ajeng Ayu Erawati,2 Bagus Aulia Mahdi,3 Satriyo Dwi Suryantoro,1 Aditea Etnawati Putri,4 Narazah Mohd Yusoff5 1Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga ...
Putri AE, Yusoff NM, Romadhon PZ, Heryana MO, Auliya K, Mahdi BA, Erawati AA, Suryantoro SD   +7 more
core  

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Dosimetric accuracy of low dose rate volumetric modulated arc therapy delivery in an Elekta Versa HD linear accelerator for pulsed low dose rate treatment of recurrent high-grade glioma using Monaco planning system: Low dose rate VMAT-based PLDR in Elekta Linac. [PDF]

J Appl Clin Med Phys
Jagadeesan S, Chamundeeswari SPV.
europepmc   +1 more source

Low dose and low dose-rate effects (173-187) [PDF]

Journal of Radiation Research, 2000
openaire   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Morphological variation in rectal hydrogel spacer one month after insertion during low-dose-rate brachytherapy for prostate adenocarcinoma. [PDF]

Radiat Oncol J
Choi H, Lee SJ, Park Y, Kim W, Lee H, Cho J.   +5 more
europepmc   +1 more source

Biological Effects of Low Dose and Low Dose Rate Irradiation

Shika Hoshasen, 2021
openaire   +1 more source

Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

, 2011
Purpose: Adjuvant high-dose-rate brachytherapy (HDRBT) offers advantages over low dose rate brachytherapy (LDRBT), although there are little data on local tumor control and treatment related toxicity. We report outcome in patients with primary, recurrent,
Donald Hackbarth, Julie A. Bradley, Sara H. Kleinman, Dian Wang, David King, Robert Whitfield, Jason Rownd   +6 more
core  

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Long-Term Outcomes of Low-Dose-Rate Brachytherapy in Localized Prostate Cancer: A 17-Year Retrospective Analysis of a Single-Center Portuguese Cohort. [PDF]

J Clin Med
Rabaça C, Roda D, Vieira G, Pereira B, Godinho R, Lourenço M, Pereira JA, Regencio M, Macedo S, Sismeiro A.   +9 more
europepmc   +1 more source